Denosumab  ||| S:0 E:10 ||| NNP
-  ||| S:10 E:12 ||| :
a  ||| S:12 E:14 ||| DT
new  ||| S:14 E:18 ||| JJ
option  ||| S:18 E:25 ||| NN
in  ||| S:25 E:28 ||| IN
the  ||| S:28 E:32 ||| DT
treatment  ||| S:32 E:42 ||| NN
of  ||| S:42 E:45 ||| IN
osteoporosis  ||| S:45 E:58 ||| JJ
Denosumab  ||| S:58 E:68 ||| NNP
is  ||| S:68 E:71 ||| VBZ
the  ||| S:71 E:75 ||| DT
international  ||| S:75 E:89 ||| JJ
name  ||| S:89 E:94 ||| NN
of  ||| S:94 E:97 ||| IN
a  ||| S:97 E:99 ||| DT
human ||| S:99 E:104 ||| JJ
,  ||| S:104 E:106 ||| ,
monoclonal  ||| S:106 E:117 ||| JJ
antibody  ||| S:117 E:126 ||| NN
approved  ||| S:126 E:135 ||| VBN
for  ||| S:135 E:139 ||| IN
the  ||| S:139 E:143 ||| DT
treatment  ||| S:143 E:153 ||| NN
of  ||| S:153 E:156 ||| IN
osteoporosis ||| S:156 E:168 ||| NN
.  ||| S:168 E:170 ||| .
This  ||| S:170 E:175 ||| DT
antibody  ||| S:175 E:184 ||| NN
is  ||| S:184 E:187 ||| VBZ
associated  ||| S:187 E:198 ||| VBN
with  ||| S:198 E:203 ||| IN
RANK  ||| S:203 E:208 ||| NNP
ligand  ||| S:208 E:215 ||| NNS
( ||| S:215 E:216 ||| -LRB-
RANKL ||| S:216 E:221 ||| NNP
) ||| S:221 E:222 ||| -RRB-
,  ||| S:222 E:224 ||| ,
inactivating  ||| S:224 E:237 ||| VBD
it ||| S:237 E:239 ||| PRP
.  ||| S:239 E:241 ||| .
In  ||| S:241 E:244 ||| IN
consequence ||| S:244 E:255 ||| NN
,  ||| S:255 E:257 ||| ,
the  ||| S:257 E:261 ||| DT
formation  ||| S:261 E:271 ||| NN
and  ||| S:271 E:275 ||| CC
survival  ||| S:275 E:284 ||| NN
of  ||| S:284 E:287 ||| IN
osteoclasts  ||| S:287 E:299 ||| NNS
are  ||| S:299 E:303 ||| VBP
suppressed ||| S:303 E:313 ||| VBN
,  ||| S:313 E:315 ||| ,
leading  ||| S:315 E:323 ||| VBG
to  ||| S:323 E:326 ||| TO
their  ||| S:326 E:332 ||| PRP$
apoptosis ||| S:332 E:341 ||| NN
.  ||| S:341 E:343 ||| .
All  ||| S:343 E:347 ||| PDT
this  ||| S:347 E:352 ||| DT
results  ||| S:352 E:360 ||| NNS
in  ||| S:360 E:363 ||| IN
lower  ||| S:363 E:369 ||| JJR
bone  ||| S:369 E:374 ||| NN
resorption ||| S:374 E:384 ||| NN
,  ||| S:384 E:386 ||| ,
while  ||| S:386 E:392 ||| IN
bone  ||| S:392 E:397 ||| NN
mineral  ||| S:397 E:405 ||| NN
density  ||| S:405 E:413 ||| NNS
( ||| S:413 E:414 ||| -LRB-
BMD ||| S:414 E:417 ||| NNP
)  ||| S:417 E:419 ||| -RRB-
increases ||| S:419 E:428 ||| NNS
.  ||| S:428 E:430 ||| .
Denosumab  ||| S:430 E:440 ||| NNP
also  ||| S:440 E:445 ||| RB
reduces  ||| S:445 E:453 ||| VBZ
the  ||| S:453 E:457 ||| DT
risk  ||| S:457 E:462 ||| NN
of  ||| S:462 E:465 ||| IN
vertebral  ||| S:465 E:475 ||| NN
and  ||| S:475 E:479 ||| CC
non-vertebral  ||| S:479 E:493 ||| JJ
fractures ||| S:493 E:502 ||| NN
.  ||| S:502 E:504 ||| .
This  ||| S:504 E:509 ||| DT
agent  ||| S:509 E:515 ||| NN
is  ||| S:515 E:518 ||| VBZ
similarly  ||| S:518 E:528 ||| RB
effective  ||| S:528 E:538 ||| JJ
in  ||| S:538 E:541 ||| IN
various  ||| S:541 E:549 ||| JJ
stages  ||| S:549 E:556 ||| NNS
of  ||| S:556 E:559 ||| IN
renal  ||| S:559 E:565 ||| JJ
function  ||| S:565 E:574 ||| NN
impairment ||| S:574 E:584 ||| NNS
;  ||| S:584 E:586 ||| :
it  ||| S:586 E:589 ||| PRP
does  ||| S:589 E:594 ||| VBZ
not  ||| S:594 E:598 ||| RB
impair  ||| S:598 E:605 ||| VB
fracture  ||| S:605 E:614 ||| JJ
healing  ||| S:614 E:622 ||| NN
processes  ||| S:622 E:632 ||| NNS
nor  ||| S:632 E:636 ||| CC
contribute  ||| S:636 E:647 ||| VB
to  ||| S:647 E:650 ||| TO
atherosclerosis  ||| S:650 E:666 ||| VB
progression  ||| S:666 E:678 ||| VBN
in  ||| S:678 E:681 ||| IN
patients  ||| S:681 E:690 ||| NNS
with  ||| S:690 E:695 ||| IN
high  ||| S:695 E:700 ||| JJ
cardiovascular  ||| S:700 E:715 ||| JJ
risks ||| S:715 E:720 ||| NNS
.  ||| S:720 E:722 ||| .
Following  ||| S:722 E:732 ||| VBG
an  ||| S:732 E:735 ||| DT
analysis  ||| S:735 E:744 ||| NN
of  ||| S:744 E:747 ||| IN
adverse  ||| S:747 E:755 ||| JJ
effects ||| S:755 E:762 ||| NNS
,  ||| S:762 E:764 ||| ,
performed  ||| S:764 E:774 ||| VBN
in  ||| S:774 E:777 ||| IN
the  ||| S:777 E:781 ||| DT
FREEDOM  ||| S:781 E:789 ||| NNP
study  ||| S:789 E:795 ||| NN
( ||| S:795 E:796 ||| -LRB-
in  ||| S:796 E:799 ||| IN
which  ||| S:799 E:805 ||| WDT
it  ||| S:805 E:808 ||| PRP
was  ||| S:808 E:812 ||| VBD
demonstrated  ||| S:812 E:825 ||| VBN
that  ||| S:825 E:830 ||| IN
the  ||| S:830 E:834 ||| DT
incidence  ||| S:834 E:844 ||| NN
of  ||| S:844 E:847 ||| IN
the  ||| S:847 E:851 ||| DT
majority  ||| S:851 E:860 ||| NN
of  ||| S:860 E:863 ||| IN
adverse  ||| S:863 E:871 ||| JJ
effects  ||| S:871 E:879 ||| NNS
observed  ||| S:879 E:888 ||| VBD
in  ||| S:888 E:891 ||| IN
the  ||| S:891 E:895 ||| DT
course  ||| S:895 E:902 ||| NN
of  ||| S:902 E:905 ||| IN
denosumab  ||| S:905 E:915 ||| JJ
use  ||| S:915 E:919 ||| NN
was  ||| S:919 E:923 ||| VBD
similar  ||| S:923 E:931 ||| JJ
to  ||| S:931 E:934 ||| TO
that  ||| S:934 E:939 ||| DT
in  ||| S:939 E:942 ||| IN
the  ||| S:942 E:946 ||| DT
placebo  ||| S:946 E:954 ||| JJ
group ||| S:954 E:959 ||| NN
) ||| S:959 E:960 ||| -RRB-
,  ||| S:960 E:962 ||| ,
its  ||| S:962 E:966 ||| PRP$
safety  ||| S:966 E:973 ||| NN
for  ||| S:973 E:977 ||| IN
patients  ||| S:977 E:986 ||| NNS
can  ||| S:986 E:990 ||| MD
definitely  ||| S:990 E:1001 ||| RB
be  ||| S:1001 E:1004 ||| VB
confirmed ||| S:1004 E:1013 ||| VBN
.  ||| S:1013 E:1015 ||| .
